Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015, Article ID 970730, 10 pages
http://dx.doi.org/10.1155/2015/970730
Review Article

Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis

Red Cross College of Nursing, Chung-Ang University, 84 Heukseok-Dong, Dongjak-Gu, Seoul 156-756, Republic of Korea

Received 16 July 2014; Revised 2 December 2014; Accepted 11 December 2014

Academic Editor: Dawn I. Velligan

Copyright © 2015 Yun-Jung Choi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Lévy, C. Agbokou, F. Ferreri, G. Chouinard, and H. C. Margolese, “Topiramate—induced weight loss in schizophrenia: a retrospective case series study,” Canadian Journal of Clinical Pharmacology, vol. 14, no. 2, pp. e234–e239, 2007. View at Google Scholar · View at Scopus
  2. W. K. Kroeze, S. J. Hufeisen, B. A. Popadak et al., “H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs,” Neuropsychopharmacology, vol. 28, no. 3, pp. 519–526, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. L. A. Templeman, G. P. Reynolds, B. Arranz, and L. San, “Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis,” Pharmacogenetics and Genomics, vol. 15, no. 4, pp. 195–200, 2005. View at Google Scholar · View at Scopus
  4. L. Maayan, J. Vakhrusheva, and C. U. Correll, “Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis,” Neuropsychopharmacology, vol. 35, no. 7, pp. 1520–1530, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. S. Coodin, “Body mass index in persons with schizophrenia,” Canadian Journal of Psychiatry, vol. 46, no. 6, pp. 549–555, 2001. View at Google Scholar · View at Scopus
  6. M. Muscatello, A. Bruno, G. Pandolfo et al., “Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study,” Journal of Psychopharmacology, vol. 25, no. 5, pp. 667–674, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. C. Henderson, X. Fan, P. M. Copeland et al., “A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain,” The American Journal of Psychiatry, vol. 162, no. 5, pp. 954–962, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. W. W. Fleischhacker, M. E. Heikkinen, J.-P. Olié et al., “Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial,” International Journal of Neuropsychopharmacology, vol. 13, no. 8, pp. 1115–1125, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. P. K. Narula, H. S. Rehan, K. E. S. Unni, and N. Gupta, “Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial,” Schizophrenia Research, vol. 118, no. 1–3, pp. 218–223, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. H. Afshar, H. Roohafza, G. Mousavi et al., “Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial,” Journal of Psychopharmacology, vol. 23, no. 2, pp. 157–162, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. T. Baptista, E. Uzcátegui, N. Rangel et al., “Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study,” Psychiatry Research, vol. 159, no. 1-2, pp. 250–253, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R.-R. Wu, J.-P. Zhao, X.-F. Guo et al., “Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study,” The American Journal of Psychiatry, vol. 165, no. 3, pp. 352–358, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. T. Baptista, N. Rangel, V. Fernández et al., “Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial,” Schizophrenia Research, vol. 93, no. 1–3, pp. 99–108, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. D. C. Henderson, X. Fan, P. M. Copeland et al., “A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain,” Acta Psychiatrica Scandinavica, vol. 115, no. 2, pp. 101–105, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. Poyurovsky, C. Fuchs, A. Pashinian et al., “Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study,” Psychopharmacology, vol. 192, no. 3, pp. 441–448, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. T. Baptista, J. Martínez, A. Lacruz et al., “Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial,” Canadian Journal of Psychiatry, vol. 51, no. 3, pp. 192–196, 2006. View at Google Scholar · View at Scopus
  17. M. Poyurovsky, V. Tal, R. Maayan, I. Gil-Ad, C. Fuchs, and A. Weizman, “The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study,” European Neuropsychopharmacology, vol. 14, no. 4, pp. 332–336, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. P. Cavazzoni, Y. Tanaka, S. M. Roychowdhury, A. Breier, and D. B. Allison, “Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial,” European Neuropsychopharmacology, vol. 13, no. 2, pp. 81–85, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Poyurovsky, I. Isaacs, C. Fuchs et al., “Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study,” American Journal of Psychiatry, vol. 160, no. 2, pp. 297–302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Poyurovsky, A. Pashinian, I. Gil-Ad et al., “Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition,” The American Journal of Psychiatry, vol. 159, no. 6, pp. 1058–1060, 2002. View at Publisher · View at Google Scholar
  21. A. Bertani, G. Perna, G. Migliarese et al., “Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study,” Pharmacopsychiatry, vol. 37, no. 5, pp. 206–210, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. T. Y.-T. Lu, A. Kupa, G. Easterbrook, and A. A. Mangoni, “Profound weight loss associated with reboxetine use in a 44-year-old woman,” British Journal of Clinical Pharmacology, vol. 60, no. 2, pp. 218–220, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. M. Poyurovsky, S. Faragian, C. Fuchs, and A. Pashinian, “Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study,” The Israel Journal of Psychiatry and Related Sciences, vol. 46, no. 3, pp. 213–220, 2009. View at Google Scholar · View at Scopus
  24. L. Radulovic, P. Weiden, and D. B. Allison, “A double-blind, placebocontrolled trial of adjunctive sibutramine for obesity in patients with schizophrenia,” in Proceedings of the Meeting of the New Clinical Drug Evaluation Unit (NCDEU '02), pp. 1–15, Rockville, Md, USA, 2002.
  25. A. J. Scheen, “Sibutramine on cardiovascular outcome,” Diabetes Care, vol. 34, no. 2, pp. S114–S119, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. S. K. Praharaj, A. K. Jana, N. Goyal, and V. K. Sinha, “Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis,” British Journal of Clinical Pharmacology, vol. 71, no. 3, pp. 377–382, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. R. L. Kolotkin, P. K. Corey-Lisle, R. D. Crosby, H. J. Kan, and R. D. McQuade, “Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care,” European Psychiatry, vol. 23, no. 8, pp. 561–566, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. J. W. Newcomer, J. A. Campos, R. N. Marcus et al., “A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine,” The Journal of Clinical Psychiatry, vol. 69, no. 7, pp. 1046–1056, 2008. View at Google Scholar · View at Scopus
  29. K. Karunakaran, T. E. Tungaraza, and G. C. Harborne, “Is clozapine—aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?” Journal of Psychopharmacology, vol. 21, no. 4, pp. 453–456, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. D. C. Henderson, X. Fan, P. M. Copeland et al., “Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients,” Journal of Clinical Psychopharmacology, vol. 29, no. 2, pp. 165–169, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. E. Ben-Menachem, M. Axelsen, E. H. Johanson, A. Stagge, and U. Smith, “Predictors of weight loss in adults with topiramate-treated epilepsy,” Obesity Research, vol. 11, no. 4, pp. 556–562, 2003. View at Google Scholar · View at Scopus
  32. G. Gobbi, P.-O. Gaudreau, and N. Leblanc, “Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis,” Journal of Clinical Psychopharmacology, vol. 26, no. 5, pp. 467–473, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. M. K. Hahn, G. Remington, D. Bois, and T. Cohn, “Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects,” Journal of Clinical Psychopharmacology, vol. 30, no. 6, pp. 706–710, 2010. View at Publisher · View at Google Scholar · View at Scopus